RT Journal Article
SR Electronic
T1 International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy
JF Pharmacological Reviews
JO Pharmacol Rev
FD American Society for Pharmacology and Experimental Therapeutics
SP 281
OP 341
DO 10.1124/pr.58.3.3
VO 58
IS 3
A1 Maria P. Abbracchio
A1 Geoffrey Burnstock
A1 Jean-Marie Boeynaems
A1 Eric A. Barnard
A1 José L. Boyer
A1 Charles Kennedy
A1 Gillian E. Knight
A1 Marta Fumagalli
A1 Christian Gachet
A1 Kenneth A. Jacobson
A1 Gary A. Weisman
YR 2006
UL http://pharmrev.aspetjournals.org/content/58/3/281.abstract
AB There have been many advances in our knowledge about different aspects of P2Y receptor signaling since the last review published by our International Union of Pharmacology subcommittee. More receptor subtypes have been cloned and characterized and most orphan receptors deorphanized, so that it is now possible to provide a basis for a future subdivision of P2Y receptor subtypes. More is known about the functional elements of the P2Y receptor molecules and the signaling pathways involved, including interactions with ion channels. There have been substantial developments in the design of selective agonists and antagonists to some of the P2Y receptor subtypes. There are new findings about the mechanisms underlying nucleotide release and ectoenzymatic nucleotide breakdown. Interactions between P2Y receptors and receptors to other signaling molecules have been explored as well as P2Y-mediated control of gene transcription. The distribution and roles of P2Y receptor subtypes in many different cell types are better understood and P2Y receptor-related compounds are being explored for therapeutic purposes. These and other advances are discussed in the present review.